It's been a rough few years for investors excited about new biopharmaceutical companies that use artificial intelligence (AI) to select new drug candidates. Less than three years after raising $510 ...

Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development. For ...

Recursion's REC-994 met safety and tolerability endpoints in the Phase 2 trial for CCM, but efficacy data were limited. Secondary endpoints showed trends toward reduced lesion size in the highest dose ...

The advent of AI is changing how drugs are developed by predicting likely outcomes without extensive testing. While drug companies seem hesitant to test-drive this tech, they'll likely eventually warm ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

Recursion Pharmaceuticals is using AI to accelerate the drug development process. The company's approach could change the way drugmakers operate. However, the biotech has yet to prove that its ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Recursion could be on the verge of transforming the drug development process. However, the company has yet to demonstrate the superiority of its strategy. Moreover, Recursion is going to face growing ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...